Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Galectin Stories

2013-05-23 08:28:46

ATLANTA, May 23, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Due to technological difficulties, a different phone number than previously circulated will be used for accessing the call. The audio portion of the call can now be accessed by dialing (888) 582-3528 (toll-free within the United States) or (847) 944-7361...

2013-05-15 08:30:19

ATLANTA, May 15, 2013 /PRNewswire/ -- Galectin Therapeutics (NASDAQ: GALT) will host a conference call at 9:30 A.M. Eastern Time on Thursday, May 23, 2013, to provide an update following the Company's Annual Meeting of Shareholders. Additionally, Peter Traber, MD, President, CEO and CMO of Galectin Therapeutics, will update the investment community on the Company's pipeline of galectin inhibitor compounds and progress in its development of treatments for liver fibrosis and cancer. Following...

2013-04-04 08:28:30

Former Silicon Valley Leaders Say Atlanta Emerging as "Silicon Valley for Biotech" and Curing Big Diseases NORCROSS, Ga., April 4, 2013 /PRNewswire/ -- Gilbert Amelio, former CEO of Apple, and Rod Martin, former counsel to PayPal, both on the Board of Directors of Galectin Therapeutics (NASDAQ: GALT) authored an opinion piece in today's Atlanta Journal Constitution discussing the future of Atlanta as the emerging Silicon Valley for changing the world by curing the big diseases, and...

2012-08-23 02:22:54

SAN FRANCISCO, Aug. 23, 2012 /PRNewswire/ -- Cancer, heart disease, chronic inflammation--these disease conditions plague humanity, causing early death and untold suffering. Slowly, scientists are uncovering their numerous causes including genetic anomalies, environmental toxins, obesity and other factors. However, a rapidly expanding body of research points to a single biological culprit that profoundly affects these and other conditions--the molecule Galectin-3. Presented at the...

2012-01-22 18:00:00

La Jolla acquires GCS-100 for treatment of cancer and chronic organ failure, appoints new CEO and director Scottsdale, AZ (PRWEB) January 22, 2012 QualityStocks would like to highlight La Jolla Pharmaceutical Co., a publicly traded biopharmaceutical company dedicated to the development of treatments that significantly improve outcomes in patients with life-threatening diseases. GCS-100, the Company´s product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular...

2009-06-15 08:00:00

WELLESLEY HILLS, Mass., June 15 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that in vitro studies have demonstrated that GCS-100 binds to and blocks the effects of galectin-3. Galectin-3 plays an important role in tumor cell survival, new blood vessel growth, cell proliferation and tumor metastasis, which is the spread of cancer beyond its primary site. As a result, this product candidate may have multiple benefits in combating cancer cells, including: Induction...